Trials / Unknown
UnknownNCT02878278
Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect,Pharmacokinetics, Pharmacodynamics and EB Virus Activation
Research About the Differences Between Chidamide Taken Daily and Twice a Week in Pharmacokinetics
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Huiqiang Huang · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
1. To compare the therapeutic effects, safety and the corresponding pharmacokinetics and pharmacodynamics between two different method of drug administration: 10mg, daily and 30mg/d, twice every week, and find out the more effect way of Chidamide administration. 2. To examine whether Chidamide could activate EB virus, and whether the above two different ways of administration are different in EB virus activation.
Detailed description
Currently, Chidamide is taken twice a week, this comes from cell experiment and phase I clinical trial, which showed that the de-acetylation effect of Chidamide could last for 72 hours after administration. However, daily administration of Chidamide may create a more steady Chidamide concentration, thus improve the de-acetylation effect of Chidamide, so it's necessary to compare the two different ways of administration. Current study showed that Romidepsin, a HDACI, could activate EBV during the treatment of NKTCL, whether Chidamide, as a novel HDACI, could activate EBV is still not clear, so this problem is worth to be accessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chidamide BIW | Chidamide is given 30mg, twice a week |
| DRUG | Chidamide QD | Chidamide is given 10mg,QD |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2019-03-01
- Completion
- 2019-09-01
- First posted
- 2016-08-25
- Last updated
- 2016-08-25
Source: ClinicalTrials.gov record NCT02878278. Inclusion in this directory is not an endorsement.